** Orthocell OCC.AX jumps 7% to A$1.53; set for biggest intraday percentage gain since March 17
** Biotech firm receives U.S. FDA clearance to begin commercially distributing its flagship Remplir nerve repair product in the U.S.
** Stock sees busiest session since late February - 3.2 million shares traded, 2.1x the 30-day avg
** OCC gains 13.3% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。